News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioPartners GmbH And LG Life Sciences, Ltd. Present Positive Phase 3, Placebo-Controlled Six Month Efficacy and Safety Data for Sustained Release Recombinant Human Growth Hormone (LB03002) Given to Adults with Growth Hormone Deficiency


6/11/2009 12:01:16 PM

BAAR, Switzerland--(BUSINESS WIRE)--Biopartners GmbH and LG Life Sciences Ltd (LGLS) today presented positive phase 3, placebo-controlled six month efficacy and safety data in adults with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth hormone, at the 91st annual meeting of the Endocrine Society (ENDO 09) in Washington, DC.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES